Liconor (Ursodeoxycholic Acid) is indicated for the treatment of:
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Liconor is used to reduce cholesterol saturation in bile and promote the gradual dissolution of cholesterol gallstones. Treatment with Ursodeoxycholic Acid reduces cholesterol secretion into bile and increases bile acid secretion without reducing phospholipid secretion.
By reducing cholesterol saturation in bile, Liconor helps convert bile from a cholesterol-supersaturated state to a less saturated state, facilitating the gradual dissolution of cholesterol gallstones.
Ursodeoxycholic Acid is a naturally occurring bile acid used in the management of various hepatobiliary disorders. Its primary action is to reduce cholesterol secretion into bile.
Ursodeoxycholic Acid works through several mechanisms, including reducing intestinal cholesterol absorption and suppressing hepatic cholesterol synthesis while preserving bile acid synthesis.
As a result, it alters bile composition from cholesterol-supersaturated to unsaturated. It also promotes the formation of liquid cholesterol crystal complexes, facilitating the removal of cholesterol from the gallbladder into the intestine for elimination.
Ursodeoxycholic Acid may improve cholestatic liver diseases by:
Ursodeoxycholic Acid is well absorbed from the upper intestine. Peak serum concentrations are generally reached within 30–150 minutes, with an absorption rate of approximately 60–80%.
After absorption, Ursodeoxycholic Acid enters the portal circulation and is taken up by the liver, where it is conjugated with glycine or taurine and subsequently secreted into the hepatic bile ducts. Small quantities enter systemic circulation, while very small amounts are excreted in the urine. The biological half-life ranges from approximately 3.5 to 5.8 days.
Dissolution of gallstones: 8–12 mg/kg/day, given either as a single bedtime dose or in divided doses.
Primary biliary cirrhosis: 10–15 mg/kg/day in 2–4 divided doses.
Acute viral hepatitis: 600 mg/day.
Alcoholic fatty liver disease: 300 mg/day.
Primary sclerosing cholangitis: 25–30 mg/kg/day.
Non-alcoholic steatohepatitis and dissolution of gallstones: 13–15 mg/kg/day.
Dosage and duration of treatment should be determined by a registered physician according to the patient's condition and response to treatment.
Liconor may interact with medicines that affect bile composition or reduce the absorption of Ursodeoxycholic Acid.
Inform your doctor about all medicines, supplements, and herbal products you are taking before starting Liconor.
Ursodeoxycholic Acid has been used during pregnancy, including in the management of cholestasis of pregnancy, under medical supervision. Available clinical experience has not demonstrated evidence of harm to the fetus.
Pregnant or breastfeeding women should consult their doctor before using Liconor. The medicine should be used during pregnancy or lactation only when considered appropriate by a healthcare professional.
Liconor should be used cautiously in patients with liver disease. Appropriate liver function monitoring may be required depending on the underlying condition and duration of treatment.
Patients receiving Liconor for gallstone dissolution may require periodic imaging to assess treatment response.
Store below 25°C. Protect from light and moisture. Keep out of the reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.